EUVIMEDEUVIMED entdecken
Crossref

Neurofilament Light Chain: A Translational Safety Biomarker for Drug-Induced Peripheral Neurotoxicity

Diethilde Theil iD, Jens Kuhle, Dominique Brees, Elaine Tritto, François Pognan, Wilfried Frieauff, Kelley Penraat, Emily Meseck iD, Reginald Valdez, Andreas Hartmann

Toxicologic Pathology · 2023

DOI: 10.1177/01926233231180179 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Toxicologic Pathology, 2023. Verfasst von Diethilde Theil und 9 weiteren Autor:innen. Beteiligte Einrichtung: Novartis Pharma AG, Basel, Switzerland. Hauptthemen laut MEDLINE: Intermediate Filaments, Neurotoxicity Syndromes. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Novartis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Branaplam is a splicing modulator previously under development as a therapeutic agent for Spinal Muscular Atrophy Type 1 and Huntington’s disease. Branaplam increased the levels of survival motor neuron protein in preclinical studies and was well tolerated in early clinical studies; however, peripheral neurotoxicity was observed in a preclinical safety study in juvenile dogs. The aim of this study was to determine whether serum neurofilament light chain (NfL) concentrations in dogs could serve as a monitoring biomarker for branaplam-induced peripheral neurotoxicity. A 30-week time-course investigative study in dogs treated with vehicle control (negative control), neurotoxic pyridoxine (positive control), or branaplam was conducted to assess neuropathology, nerve morphometry, electrophysiological measurements, gene expression profiles, and correlation to NfL serum concentrations. In branaplam-treated animals, a mild to moderate nerve fiber degeneration was observed in peripheral nerves correlating with increased serum NfL concentrations, but there were no observed signs or changes in electrophysiological parameters. Dogs with pyridoxine-induced peripheral axonal degeneration displayed clinical signs and electrophysiological changes in addition to elevated serum NfL. This study suggests that NfL may be useful as an exploratory biomarker to assist in detecting and monitoring treatment-related peripheral nerve injury, with or without clinical signs, associated with administration of branaplam and other compounds bearing a neurotoxic risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Intermediate FilamentsNeurotoxicity SyndromesAnimalsDogsPyridoxineBiomarkersNerve Degeneration

Stichwörter der Autor:innen

branaplamneurofilamentperipheral neuropathy

Substanzen

PyridoxineBiomarkers

Autor:innen und Institutionen

  • Novartis Pharma AG, Basel, Switzerland.
  • F. Hoffmann-La Roche AG, Basel, Switzerland.
  • University Hospital Basel, Switzerland.
  • Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, USA.
  • Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
  • Amgen, Inc., Cambridge, Massachusetts, USA.

ORCID-Profile: Diethilde Theil, Emily Meseck

Förderung

  • Novartis

Zitieren

APA

Theil, D., Kuhle, J., Brees, D., Tritto, E., Pognan, F., Frieauff, W., Penraat, K., Meseck, E., Valdez, R., & Hartmann, A. (2023). Neurofilament Light Chain: A Translational Safety Biomarker for Drug-Induced Peripheral Neurotoxicity. Toxicologic Pathology. https://doi.org/10.1177/01926233231180179

Vancouver

Theil D, Kuhle J, Brees D, Tritto E, Pognan F, Frieauff W, et al. Neurofilament Light Chain: A Translational Safety Biomarker for Drug-Induced Peripheral Neurotoxicity. Toxicologic Pathology. 2023. doi:10.1177/01926233231180179

BibTeX
@article{Theil2023,
  author = {Theil, Diethilde and Kuhle, Jens and Brees, Dominique and Tritto, Elaine and Pognan, François and Frieauff, Wilfried and Penraat, Kelley and Meseck, Emily and Valdez, Reginald and Hartmann, Andreas},
  title = {Neurofilament Light Chain: A Translational Safety Biomarker for Drug-Induced Peripheral Neurotoxicity},
  journal = {Toxicologic Pathology},
  year = {2023},
  doi = {10.1177/01926233231180179}
}
Kostenlos starten →